SSR 146977: a tachykinin NK3 receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 9938990 |
SCHEMBL ID | 16566367 |
MeSH ID | M0443189 |
Synonym |
---|
gtpl2133 |
3-[1-[3-[(3r)-1-(benzoyl)-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-1,1-dimethylurea |
ssr 146977 |
cas-264618-44-2 |
tox21_300229 |
NCGC00254193-01 |
dtxsid8047341 , |
ssr146977 |
dtxcid201333802 |
SCHEMBL16566367 |
NCGC00370814-01 |
3-[1-[3-[(3r)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-1,1-dimethylurea |
ssr-146977 |
Q27088877 |
CS-0066604 |
HY-116822 |
AKOS040745373 |
SSR 146977 is a potent and selective antagonist of the tachykinin NK3 receptor.
Excerpt | Reference | Relevance |
---|---|---|
"SSR 146977 is a potent and selective antagonist of the tachykinin NK3 receptor. " | ( Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist. Advenier, C; Daoui, S; Emonds-Alt, X; Gueudet, C; Le Fur, G; Maffrand, JP; Michaud, JC; Naline, E; Oury-Donat, F; Pascal, M; Poncelet, M; Proietto, V; SoubriƩ, P; Steinberg, R; Vilain, P, 2002) | 2.02 |
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
SMAD family member 2 | Homo sapiens (human) | Potency | 10.4094 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
SMAD family member 3 | Homo sapiens (human) | Potency | 10.4094 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
AR protein | Homo sapiens (human) | Potency | 12.6296 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743036; AID743063 |
cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 1.5092 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 10.4094 | 0.0002 | 14.3764 | 60.0339 | AID720691 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 10.4784 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 13.1046 | 0.3758 | 27.4851 | 61.6524 | AID743220 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 8.1961 | 0.0002 | 29.3054 | 16,493.5996 | AID743079 |
G | Vesicular stomatitis virus | Potency | 21.3174 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
cytochrome P450 2D6 | Homo sapiens (human) | Potency | 3.3786 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 3.2917 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 9.2774 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 12.8845 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743066; AID743067 |
Interferon beta | Homo sapiens (human) | Potency | 21.3174 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 21.3174 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 21.3174 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 21.3174 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346386 | Human NK3 receptor (Tachykinin receptors) | 2002 | Canadian journal of physiology and pharmacology, May, Volume: 80, Issue:5 | Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.28) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |